Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857463 | 0.95 | ALDH1A1 (0.44) | CNR1ALDH1A1MEN1KMT2AFKBP1A | |
| SCHEMBL6805205 | 0.86 | CNR1 (0.45) | CNR1ALDH1A1MEN1KMT2AFKBP1A | |
| SCHEMBL5915288 | 0.76 | L3MBTL1 (0.54) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL6809424 | 0.75 | ALDH1A1 (0.68) | CNR1ALDH1A1MEN1KMT2AFKBP1A | |
| SCHEMBL6809422 | 0.75 | ALDH1A1 (0.68) | CNR1ALDH1A1MEN1KMT2AFKBP1A | |
| SCHEMBL4610558 | 0.74 | ACLY (0.53) | — | |
| SCHEMBL3316800 | 0.73 | CYP2C9 (0.50) | ALDH1A1KDM4EPOLB | |
| SCHEMBL27974779 | 0.72 | CNR1 (0.54) | CNR1ALDH1A1MEN1KMT2ATMEM97 | |
| SCHEMBL6810032 | 0.69 | PSEN1 (0.66) | ALDH1A1MEN1KMT2AITGB1ITGA4 | |
| SCHEMBL2220456 | 0.68 | KDM2B (0.51) | CNR1ALDH1A1MEN1KMT2AFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-07-08 | — | — | US | claimed |
| US-6630503-B1 | Non-peptidic sulfonamide compounds that specifically inhibit the binding of ligands to VLA-4 for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and pathologies such as inflammation and immune reactions | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | CNR1 1859/4885ALDH1A1 631/4885MEN1 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.